← All trials
NCT04671433
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2021
- Primary completion
- Jul 5, 2022
- Completion date
- Jul 5, 2022
- First posted
- Dec 17, 2020
- Last posted
- Sep 27, 2021
- Enrollment
- 66
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MeiraGTxLead sponsor
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.